<DOC>
	<DOCNO>NCT00715793</DOCNO>
	<brief_summary>The combination TMZ DAC may effect dual modulation DNA repair gene result improved clinical response .</brief_summary>
	<brief_title>Combination Decitabine Temozolomide Treatment Patients With Metastatic Melanoma</brief_title>
	<detailed_description>Primary Objectives : - Phase I : To determine safety , tolerability , Phase II recommend dose combination extend schedule TMZ DAC . - Phase II : To determine efficacy , measure overall response rate , combination extend schedule TMZ DAC give Phase II recommend dose patient metastatic melanoma . Secondary Objectives : - To determine pharmacokinetics combination TMZ DAC patient metastatic melanoma . - To determine , peripheral blood mononuclear cell ( PBMC ) tumor tissue , pharmacodynamic effect combination TMZ DAC promoter methylation expression select gene correlate response . - To determine progression-free survival patient treat combination TMZ DAC .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients nonresectable Stage IIIB stage IV metastatic melanoma progress despite prior therapy . Life expectancy least 12 week . ECOG performance status 0 , 1 2 . â‰¥18 year age . Patients receive chemotherapeutic , biological investigational agent within 28 day study drug administration . First line active brain metastasis ( metastatic lesion brain adequately treat surgery and/or appropriate radiation therapy document stability &gt; 4 week &gt; 2 week treat stereotactic radiosurgery , remain eligible ) Any evidence renal dysfunction ( proteinuria , estimate creatinine clearance serum creatinine test &lt; 60 ml/min ) . Impaired hepatic function ( liver enzymes great twice upper limit normal bilirubin &gt; 2.0 except patient Gilbert 's syndrome ) . Prior treatment alkylating agent ( include TMZ DTIC ) . Active brain metastasis ( metastatic lesion brain adequately treat surgery and/or appropriate radiation therapy document stability &gt; 4 week remain eligible ) . Active infection serious general medical condition . Female patient childbearing age adequate contraception , pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Decitabine</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Non-resectable</keyword>
	<keyword>Stage IIIB melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>TMZ</keyword>
	<keyword>DTIC</keyword>
	<keyword>promoter methylation</keyword>
	<keyword>skin cancer</keyword>
	<keyword>chemotherapy</keyword>
</DOC>